Clinical Trial Update: RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update for RGX-121 gene therapy in children aged 5 and older with Mucopolysaccharidosis Type II (Hunter syndrome); the study has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis Type Ii

Drugs mentioned

• RGX-121

Snippet

Sponsor: REGENXBIO Inc. | Conditions: Mucopolysaccharidosis Type II (MPS II) | Phase 1, Phase 2 | Status: COMPLETED